Menu Back to Pharmacovigilance-and-Risk-Management

Overview

Short Course
Conference: January 24-26

Safety monitoring of medicines is imperative for ensuring health and wellbeing of patients worldwide. For pharmacovigilance professionals, the complexity of safety and pharmacovigilance efforts is heightened by the rapid development of multiple vaccines and treatments, the emergent nature of knowledge about the etiology of the corona virus disease, and pervasive misinformation about prevention and treatment practices. The current challenges are ongoing and will have lasting impact on safety, pharmacovigilance, and other related PV activities, such as risk management.

DIA's Global Pharmacovigilance and Risk Management Strategies Conference provides the foundation for strong strategic planning and practical decision-making in pharmacovigilance programs. Developed by recognized experts from the biopharmaceutical industry and global regulatory agencies, this conference provides the background, context, and opportunities to discuss current challenges and to problem-solve around issues that matter most to professionals working in the field.

For this year’s program, stakeholders from medicines research, global regulation, and healthcare will join to analyze the challenges for safety and pharmacovigilance efforts in this uncertain environment and examine effective strategies for addressing gaps and needs. New approaches and collaborations that build on the foundation of sound pharmacovigilance principles to optimize safety and pharmacovigilance practice and ensure safe medicines for patients will be explored, in a global and regional context.

Social distancing measures may be in place at the time of the event. Therefore, we encourage you to register and make your housing arrangements early due to potential limited capacity. If the capacity limit is reached, we will only be able to offer the virtual option. Don’t miss out on your chance to meet live again with your friends and colleagues!

Program Committee

  • Stephen  Knowles, MD, MRCP
    Stephen Knowles, MD, MRCP Chief Medical Officer
    Halozyme Therapeutics, United States
  • Annette  Stemhagen, DrPH, FISPE
    Annette Stemhagen, DrPH, FISPE Senior Vice President and Chief Scientific Officer
    UBC, United States
  • Mariette  Boerstoel-Streefland, MD, MBA, MS
    Mariette Boerstoel-Streefland, MD, MBA, MS Senior Vice President Global Drug Safety
    Alexion Pharmaceuticals, Inc., United States
  • James  Buchanan, PharmD
    James Buchanan, PharmD President
    Covilance LLC, United States
  • Cheryl  Campbell, MS
    Cheryl Campbell, MS Associate Director of Executive Operations/Outreach and Communications, OSE,CDER
    FDA, United States
  • E. Stewart  Geary, MD
    E. Stewart Geary, MD Senior Vice President and CMO
    Eisai Co., Ltd., Japan
  • Jeremy  Jokinen, PhD, MS
    Jeremy Jokinen, PhD, MS Vice President, Epidemiology, Safety Science, Capabilities and Innovation
    Bristol-Myers Squibb Company, United States
  • Jamie  Klucken, PharmD
    Jamie Klucken, PharmD FDA/CDER/OSE/Division of Pharmacovigilance
    FDA, United States
  • Linda J. Scarazzini, MD, RPh
    Linda J. Scarazzini, MD, RPh Vice President, Pharmacovigilance and Patient Safety
    AbbVie, United States
  • Sarah  Vaughan
    Sarah Vaughan Pharmacovigilance Information Unit Systems Manager
    Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
  • Annette S. Williams, MBA, RPh
    Annette S. Williams, MBA, RPh Vice President, Pharmacovigilance
    IQVIA, United States
  • Jo  Wyeth, PharmD
    Jo Wyeth, PharmD Associate Director for Postmarket Assessments, OMEPRM, OSE, CDER
    FDA, United States
Load More

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download